Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 30;25(11):6037.
doi: 10.3390/ijms25116037.

Intestinal Microbiota and Derived Metabolites in Myocardial Fibrosis and Postoperative Atrial Fibrillation

Affiliations

Intestinal Microbiota and Derived Metabolites in Myocardial Fibrosis and Postoperative Atrial Fibrillation

Antonio Nenna et al. Int J Mol Sci. .

Abstract

The high incidence of atrial fibrillation (AFib) following cardiac surgery (postoperative atrial fibrillation, POAF) relies on specific surgical features. However, in the setting of POAF, the role of the microbiome in the modulation of cardiac fibrosis is still not clear. This study aimed to analyze the effect of the microbiome and its main metabolic product (trimethylamine-N-oxide, TMAO) in the fibrosis of myocardial tissue, to investigate its role in POAF. Patients undergoing elective cardiac surgery with cardiopulmonary bypass, central atrio-caval cannulation and no history of AFib, were included. A fragment of the right atrium was analyzed for qualitative and mRNA-quantitative evaluation. A preoperative blood sample was analyzed with enzyme-linked immunosorbent assay (ELISA). A total of 100 patients have been included, with POAF occurring in 38%. Histologically, a higher degree of fibrosis, angiogenesis and inflammation has been observed in POAF. Quantitative evaluation showed increased mRNA expression of collagen-1, collagen-3, fibronectin, and transforming growth factor beta (TGFb) in the POAF group. ELISA analysis showed higher levels of TMAO, lipopolysaccharide and TGFb in POAF, with similar levels of sP-selectin and zonulin. TMAO ≥ 61.8 ng/mL (odds ratio, OR 2.88 [1.35-6.16], p = 0.006), preoperative hemoglobin < 13.1 g/dL (OR 2.37 [1.07-5.24], p = 0.033) and impaired right ventricular function (OR 2.38 [1.17-4.83], p = 0.017) were independent predictors of POAF. Also, TMAO was significantly associated with POAF by means of increased fibrosis. Gut microbiome product TMAO is crucial for myocardial fibrosis, which is a key factor for POAF. Patients in preoperative sinus rhythm who will develop POAF have increased genetic expression of pro-fibrotic genes and enhanced fibrosis in histological staining. Elevated TMAO level (≥61.8 ng/mL) is an independent risk factor for POAF.

Keywords: atrial fibrillation; cardiac surgery; fibrosis; microbiome; microbiota.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Relative gene expression (graphical visualization of data shown in Table 4). Statistically significant inter-group differences (POAF vs. No POAF) are marked as ** (if p < 0.01) or * (if p < 0.05) on top of the relevant column.
Figure 2
Figure 2
Box plot for ELISA analysis (graphical visualization of data shown in Table 5). Statistically significant inter-group differences (POAF vs. No POAF) are marked as ** (if p < 0.01) on top of the relevant box.
Figure 3
Figure 3
Dot plot of the odds ratio relative to the final model in Table 9.

References

    1. Chen Y.C., Voskoboinik A., Gerche A., Marwick T.H., McMullen J.R. Prevention of Pathological Atrial Remodeling and Atrial Fibrillation, JACC State-of-the-Art Review. J. Am. Coll Cardiol. 2021;77:2846–2864. doi: 10.1016/j.jacc.2021.04.012. - DOI - PubMed
    1. Xintarakou A., Tzeis S., Psarras S., Asvestas D., Vardas P. Atrial fibrosis as a dominant factor for the development of atrial fibrillation, facts and gaps. Europace. 2020;22:342–351. doi: 10.1093/europace/euaa009. - DOI - PubMed
    1. Shen M.J., Arora R., Jalife J. Atrial Myopathy. JACC Basic Transl. Sci. 2019;4:640–654. doi: 10.1016/j.jacbts.2019.05.005. - DOI - PMC - PubMed
    1. Sohns C., Marrouche N.F. Atrial fibrillation and cardiac fibrosis. Eur. Heart J. 2020;41:1123–1131. doi: 10.1093/eurheartj/ehz786. - DOI - PubMed
    1. Nattel S. Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation. JACC Clin. Electrophysiol. 2017;3:425–435. doi: 10.1016/j.jacep.2017.03.002. - DOI - PubMed